Primary systemic treatment of advanced @entity978 with EVA ( XXXX , @entity5713 , @entity632 ): 10-year follow-up.

@entity632 @entity1 @entity137 @entity390 @entity2699 @entity706 @entity5 @entity391 @entity3794 @entity2879 @entity358 @entity1732 @entity978 @entity5713
BACKGROUND: The most commonly used regimen for the treatment of advanced @entity978 ( @entity978 ) is ABVD ( @entity632 , @entity1732 , @entity5713 and @entity2699 ). Two of these components, @entity1732 and @entity2699 , have defined @entity137 such as @entity3794 and @entity390 / @entity391 , and also uncertain single-drug activity. The EVA regimen ( @entity2879 , @entity5713 , @entity632 ) is an attempt to substitute a known active agent, @entity2879 , for @entity1732 and @entity2699 . @entity1 AND METHODS: A series of 51 @entity1 with advanced @entity978 without prior systemic therapy were treated. The series included 12 stage II @entity1 with bulky (>10 cm) mediastinal @entity5 , 10 of whom received complementary radiation therapy. The remaining @entity1 received EVA only. Response, duration of response, survival, @entity137 and the efficacy of salvage therapy were evaluated in all @entity1 . The median follow-up time was 111 months and permitted an assessment of the long-term effects of treatment and natural history of a cohort of treated @entity1 . RESULTS: EVA achieved a complete response (or clinical complete response) in 48/51 @entity1 (94%). Of these 48 responders, 16 relapsed in a median of 11 months (range 3-48 months). In follow-up, 32/51 @entity1 had no evidence of relapsed @entity978 , although three died from other causes (two from vascular events and one from @entity706 ), resulting in progression-free survival for the entire group of 57% at 111 months. Eight of the 16 were alive and free from disease at follow-up at 111 months. In the entire series, only seven @entity1 (14%) died of @entity978 . 37 @entity1 (73%) continued free from disease. There was no @entity358 . CONCLUSIONS: The EVA regimen appears to have an overall survival (OS) outcome comparable to ABVD, but without the @entity358 . The high salvage rate of second-line therapy, in most instances at conventional dosage, suggests an absence of cross-resistance to alkylating agents in @entity1 treated with EVA.
